Multiples Alternate buys into BDR Pharma, invests Rs 750 cr

ET was the first to report in July last year that global and domestic PE funds were in initial discussions to purchase a minority stake in the drugmaker, whose portfolio includes Covid-19 drugs remdesivir, favipiravir, molnupiravir and baricitinib in India. It is also the exclusive manufacturing partner of Cipla for remdesivir.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news